1 Overview of Transgenic Mouse Models for Alzheimer's Disease.

2 Prohibitin 2: At a communications crossroads.

3 Retraction for Ramos et al., The second RNA chaperone, Hfq2, is also required for survival under stress and full virulence of Burkholderia cenocepacia J2315.

4 Retraction notice to “Differential impact of diabetes and hypertension in the brain: adverse effects in grey matter” [Neurobiol. Dis., 44 (2011) 161–173, http://dx.doi.org/10.1016/ j.nbd.2011.06.005].

5 [Response to the response of the authors (DOI: 10.1016 / j.neuchi.2014.05.001), following our "expert opinion" (DOI: 10.1016 / j.neuchi.2014.06.001)].

6 [Response to the opinion of the expert Samuel Malca, regarding the article "Ruptured aneurysm of the hepatic artery after lumbar spinal stenosis surgery. Forensic Reflections "(Neurosurgery 2014; 60 (1-2): 38-41 DOI: 10.1016 / j.neuchi.2013.08.006.)].

7 [Expert opinion on the article: "Ruptured aneurysm of the hepatic artery after lumbar spinal stenosis surgery. Forensic Reflections "(Neurosurgery 2014; 60 (1-2): 38-41 DOI: 10.1016 / j.neuchi.2013.08.006.)].

8 WITHDRAWN: Ivory vertebra and systemic mastocytosis. Comments on the article by Frenzel et al.

9 Comment on "Ccl2, Cx3cr1 and Ccl2/Cx3cr1 chemokine deficiencies are not sufficient to cause age-related retinal degeneration" by Luhmann et al. (Exp. Eye Res. 2013; 107: 80.doi: 10.1016).

10 DIFFUSE LEWY BODY DISEASE

11 Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

12 Cholinesterase inhibitors for Alzheimer's disease

13 Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.

14 Alzheimer's disease against peptides products of enzymatic cleavage APP protein: Biological, pathobiological and physico-chemical properties of fibrillating peptides

15 Cholinesterase inhibitors as Alzheimer's therapeutics (Review).

16 Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.

17 Reconsideration of anticholinesterase therapeutic strategies against alzheimer's disease

18 Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.

19 Discovery of N-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer's disease: Synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP <sup>C</sup> interactions

20 Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D<inf>3</inf> ameliorating memory dysfunction in sporadic dementia of Alzheimer's type

21 Investigation of the Effects of Biochemical Parameters on Alzheimer's Disease.

22 Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships

23 Longitudinal brain atrophy patterns and neuropsychological performance in older adults with HIV-associated neurocognitive disorder compared with early Alzheimer's disease.

24 The Model of Aging Acceleration Network Reveals the Correlation of Alzheimer's Disease and Aging at System Level.

25 Early Alzheimer's disease-type pathology in the frontal cortex of wild mountain gorillas (Gorilla beringei beringei).

26 Fecal metabolite of a gnotobiotic mouse transplanted with gut microbiota from a patient with Alzheimer's disease.

27 Visual perceptual disorders in Alzheimer's disease.

28 Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.

29 Meta-Analysis of Gene Expression and Identification of Biological Regulatory Mechanisms in Alzheimer's Disease.

30 Corrigendum to “Fuzzy adaptive cognitive stimulation therapy generation for Alzheimer's sufferers: Towards a pervasive dementia care monitoring platform” (Future Generation Computer Systems (2018) 88 (479–490), (S0167739X1830089X) (10.1016/j.future.2018.06.018))

31 Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of ε4 on Alzheimer's Disease Risk in a Multiracial Sample.

32 Advance of sporadic Alzheimer's disease animal models.

33 Evaluation of the Music Engagement Program for people with Alzheimer's disease and dementia: Study protocol for a pilot trial.

34 Molecular Inverse Comorbidity between Alzheimer's Disease and Lung Cancer: New Insights from Matrix Factorization.

35 [Alzheimer's disease and related disorders: specificity of young onset patients, including ethical aspects].

36 The "rights" of precision drug development for Alzheimer's disease.

37 Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease.

38 Radiosynthesis of carbon-11 labeled PDE5 inhibitors as new potential PET radiotracers for imaging of Alzheimer's disease.

39 Dynamic structural determinants underlie the neurotoxicity of the N-terminal tau 26-44 peptide in Alzheimer's disease and other human tauopathies.

40 White matter alterations in early-stage Alzheimer's disease: A tract-specific study.

41 Risk estimation before progression to mild cognitive impairment and Alzheimer's disease: an AD resemblance atrophy index.

42 Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease.

43 Prediction of Alzheimer's disease based on deep neural network by integrating gene expression and DNA methylation dataset

44 Alzheimer's disease-like pathology-triggered oxidative stress, alterations in monoamines levels, and structural damage of locus coeruleus neurons are partially recovered by a mix of proteoglycans of embryonic genesis

45 Synaptic and memory dysfunction in a β-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine

46 Defective autophagy and Alzheimer's disease: Is calcium the key?

47 Differentiating between Alzheimer's disease, amnestic mild cognitive impairment, and normal aging via diffusion kurtosis imaging

48 Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer's disease

49 Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's disease

50 The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease

51 Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer's Disease?

52 Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease

53 CBIR system using Capsule Networks and 3D CNN for Alzheimer's disease diagnosis

54 Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid.

55 Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.

56 Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.

57 Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.

58 "Muscle-Gut-Brain Axis": Can Physical Activity Help Patients with Alzheimer's Disease Due to Microbiome Modulation?

59 Toward common mechanisms for risk factors in Alzheimer's syndrome.

60 Alzheimer's Disease Affects Severity of Asthma Through Methylation Control of Foxp3 Promoter.

61 Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.

62 Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid.

63 Plasma cortisol is associated with cerebral hypometabolism across the Alzheimer's disease spectrum.

64 Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer's Disease.

65 Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer's disease: a preclinical study in rTg4510 mice.

66 Time to test antibacterial therapy in Alzheimer's disease.

67 Exposure to general anesthesia and risk of alzheimer's disease: a systematic review and meta-analysis

68 Vitamin Supplementation as an Adjuvant Treatment for Alzheimer's Disease.

69 Restoration of Olfactory Memory in Overexpressing Human Alzheimer's Disease Associated Tau by Manipulation of L-Type Ca Channels.

70 No relationship between fornix and cingulum degradation and within-network decreases in functional connectivity in prodromal Alzheimer's disease.

71 Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume.

72 Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.

73 Synthesis of novel chromenones linked to 1,2,3-triazole ring system: Investigation of biological activities against Alzheimer's disease

74 Radiosynthesis of a carbon-11 labeled tetrahydrobenzisoxazole derivative as a new PET probe for γ-secretase imaging in Alzheimer's disease.

75 Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer's Disease.

76 Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study.

77 Bayesian hidden Markov models for delineating the pathology of Alzheimer's disease.

78 Recognition of Famous and Unfamiliar Faces among Patients Suffering from Amnesia Mild Cognitive Impairment (AMCI) and Alzheimer's Disease.

79 Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease.

80 Alterations of Transcription of Genes Coding Anti-oxidative and Mitochondria-Related Proteins in Amyloid β Toxicity: Relevance to Alzheimer's Disease.

81 Therapeutic effects of Cyperus rotundus rhizome extract on memory impairment, neurogenesis and mitochondria in beta-amyloid rat model of Alzheimer's disease.

82 Circadian learning and memory changes in Aβ1-42 induced Alzheimer's mice.

83 Coping Strategies Utilized by Middle-Aged and Older Latino Caregivers of Loved Ones with Alzheimer's Disease and Related Dementia.

84 Dietary pattern in relation to the risk of Alzheimer's disease: a systematic review.

85 MIND food and speed of processing training in older adults with low education, the MINDSpeed Alzheimer's disease prevention pilot trial.

86 Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease.

87 To treat or not to treat Alzheimer's disease by the ketogenic diet? That is the question

88 Passive Digital Signature for Early Identification of Alzheimer's Disease and Related Dementia.

89 Effects of Vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer's disease: A randomised, double-blind, placebo-controlled trial

90 Expert insights: The potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer's disease and hepatic encephalopathy.

91 Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals

92 Corrigendum to ‘Alteration of scaffold: Possible role of MACF1 in Alzheimer's disease pathogenesis’ (Medical Hypotheses (2019) 130, (S0306987719302853), (10.1016/j.mehy.2019.109259))

93 Subtypes of Alzheimer's Disease Display Distinct Network Abnormalities Extending Beyond Their Pattern of Brain Atrophy.

94 Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

95 Multi-modal neuroimaging feature selection with consistent metric constraint for diagnosis of Alzheimer's disease.

96 BIN1 rs744373 variant shows different association with Alzheimer's disease in Caucasian and Asian populations.

97 Mercury and Alzheimer's Disease: Hg(II) Ions Display Specific Binding to the Amyloid-β Peptide and Hinder Its Fibrillization.

98 Integrated Genomic Analysis Revealed Associated Genes for Alzheimer's Disease in APOE4 Non-Carriers.

99 Novel ligand-based docking; molecular dynamic simulations; and absorption, distribution, metabolism, and excretion approach to analyzing potential acetylcholinesterase inhibitors for Alzheimer's disease

100 Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease.

101 [Drug Repositioning for Alzheimer's Disease].

Keyword Connections

Journals

Research Groups

Bibliographies